# Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

> **NCT00361634** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 14 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00361634
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-08
- **Final completion:** 2010-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361634, "Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00361634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*